Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

63 results about "Fusobacterium" patented technology

Fusobacterium is a genus of anaerobic, Gram-negative, non-sporeforming bacteria, similar to Bacteroides. Individual cells are slender' rod-shaped bacilli with pointed ends. Strains of Fusobacterium cause several human diseases, including periodontal diseases, Lemierre's syndrome, and topical skin ulcers.

Oral cavity microorganism for identifying taste sensitivity as well as identification method and application of oral cavity microorganism

The invention belongs to the technical field of microorganisms, and particularly relates to an oral microorganism for identifying taste sensitivity as well as an identification method and application of the oral microorganism. On the basis of comparative study of young and old population, a screened oral microorganism combination covers wide characteristics of taste sensitivity difference, and the abundance of one or more of five oral microorganisms of a Haemophilus genus, a Fusobacterium genus, an Aggregate genus, a Lacnoanaerobacter genus and an Oribacterium genus is in significant positive correlation with the taste sensitivity, so that the oral microorganism combination can be used for accurately identifying the oral microorganisms of one or more of the five oral microorganisms of the Haemophilus genus, the Fusobacterium genus, the Aggregate genus, the Lacnoanaerobacter genus and the Oribacterium genus.
Owner:BEIJING TECH & BUSINESS UNIV

Meningioma saliva microbial marker, product and application thereof

The invention discloses a meningioma saliva microbial marker, a product and application of the meningioma saliva microbial marker, and belongs to the field of biological medicine. The saliva microbial marker is prepared from one or more of fusobacterium periodontium, neisseria microflavus, and Streptococcus cristatum, and the saliva microbial marker is prepared from one or more of the following components: the fusobacterium periodontium, the neisseria microflavus, and the Streptococcus cristatum, and the saliva microbial marker is prepared from one or more of the following components: the Saccharomyces cerevisiae, the Saccharomyces cerevisiae, the Saccharomyces cerevisiae and the Saccharomyces cristatum. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the saliva microbial marker. The invention provides a product for diagnosing meningioma and a computer program product related to meningioma. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of meningioma, and provides a new tool for clinical diagnosis.
Owner:ZHONGNAN HOSPITAL OF WUHAN UNIV +1

Bacillus coagulans for feed expression bacteriocin and application thereof

The invention discloses bacillus coagulans for feed expression bacteriocin and application of the bacillus coagulans. The bacillus coagulans BCH0 (preservation number is CGMCC (China General Microbiological Culture Collection Center) No.26478) is gram-positive bacteria, spores are formed at the end, and the bacillus coagulans BCH0 is obtained by breeding after a soil sample is subjected to anaerobic enrichment culture in improved bromcresol purple glucose broth at 55 DEG C. The strain can tolerate the high temperature of 80 DEG C, has good acid resistance, is sensitive to 28 antibiotics such as penicillin, tetracycline and polymyxin, and can be applied to the field of biological engineering. The bacillus coagulans and the bacteriocin of the bacillus coagulans are safe and effective when being used for feeding animals, the growth performance of the broiler chickens can be effectively improved when the broiler chickens are fed, and the feed conversion efficiency is improved.
Owner:CHINA AGRI UNIV

Microbial marker combination for predicting colorectal cancer neoadjuvant chemotherapy sensitivity and application thereof

The invention relates to the technical field of biological detection, and particularly discloses a microbial marker combination for predicting neoadjuvant chemotherapy sensitivity of colorectal cancer and application of the microbial marker combination, and the microbial marker combination comprises treponema, staphylococcus, streptococcus, facultative diplococcus and fusobacterium. The invention further discloses a method for predicting the neoadjuvant chemotherapy sensitivity of colorectal cancer and application of the microbial marker combination for predicting the neoadjuvant chemotherapy sensitivity of colorectal cancer and application of the microbial marker combination for predicting the neoadjuvant chemotherapy sensitivity of colorectal cancer, and the microbial marker combination comprises treponema, staphylococcus, streptococcus, facultative diplococcus and fusobacterium. According to the application, by analyzing the microbial community composition in the tumor microenvironment of the colorectal cancer patient, the microbial marker related to the neoadjuvant chemotherapy sensitivity is identified, the patient insensitive to neoadjuvant chemotherapy can be accurately predicted based on the microbial marker combination disclosed in the application, the treatment risk is reduced, the invalid treatment is reduced, and the treatment effect is improved. And a reliable basis is provided for formulating precise personalized treatment.
Owner:HEFEI INSTITUTE OF PHYSICAL SCIENCE CHINESE ACADEMY OF SCIENCES

Nano-drug preparation for tumor treatment and preparation method and application of nano-drug preparation

The invention provides a nano medicinal preparation for tumor treatment as well as a preparation method and application thereof, and relates to the technical field of medicinal preparations. The preparation method of the nano medicinal preparation comprises the following steps: S1, adding metal salt and oxidase into water, uniformly stirring and mixing to form a compound, then adding antibiotics, and continuously stirring and uniformly mixing for reaction to obtain a mixed solution; and S2, centrifuging the mixed solution, collecting the precipitate, washing, and dispersing into water for storage to obtain the nano-drug preparation. The nano medicinal preparation disclosed by the invention can intelligently respond to a tumor microenvironment, efficiently remove fusobacterium nucleatum in tumors and kill tumor cells through synergistic antibacterial and anticancer effects, so that tumor development is inhibited. Moreover, the complex prepared by the invention can enhance the stability of a medicinal preparation, can realize targeted release of the medicine in a tumor microenvironment, and improves the action effect.
Owner:TAIZHOU ENZE MEDICAL CENT GROUP +1

Compositions for controlling fusobacterium bacteria in intestinal flora and uses thereof

The present invention addresses the problem of providing a composition for controlling bacteria belonging to the genus Fusobacterium among the intestinal flora. The present invention provides a composition for controlling a bacterium belonging to the genus Fusobacterium in the intestinal flora, the composition comprising a bacterium belonging to the family Lactobacillus. The bacterium belonging to the genus fusobacterium is preferably a fusobacterium nucleatum (fusobacterium nucleatum), and the bacterium belonging to the genus fusobacterium is preferably a fusobacterium nucleatum (fusobacterium nucleatum). It is preferable that the bacterium belonging to the family Lactobacillus belong to a bacterium belonging to any genus selected from the group consisting of the genus Lactobacillus, the genus Lactobacillus, the genus Limosilbacilli, the genus Liiilbacilli, the genus Lactobacillus lactis, the genus Lactobacillus casei, and the genus Lactobacillus plantarum, and that the bacterium belonging to the family Lactobacillus is a bacterium belonging to any genus selected from the group consisting of the genus Lactobacillus, the genus Lactobacillus lactis, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus and the genus Lactobacillus acidophilus.
Owner:MEIJI CO LTD

Small molecule inhibitors of bacterial toxins

Described herein are compounds and compositions for use in treatment or prevention of an inflammatory bowel disease, gastrointestinal cancer, or a systemic bacterial infection in a subject in need thereof. They subject may be colonized by one or more pathogenic bacterial strains such as B. fragilis, E. faecalis, or C. perfringens. In certain aspects, the disclosure provides a method of diminishing the pathogenic effects of these bacterial stmins by administering a compound that binds to and / or inhibits one or more toxins produced thereby.
Owner:PIPR THERAPEUTICS INC

A beneficial bacterium for colorectal cancer prevention and inhibition of pathogenic bacteria

PCT designated stageWO2025232059A1Organic active ingredientsBacteriaMetaboliteFaecalibacterium prausnitzii
A probiotic composition for inhibiting the onset and progression of colorectal cancer, comprises one or more of a culture supernatant of Faecalibacterium prausnitzii (Fp) cells, live Fp cells, or non-viable Fp cells,wherein the probiotic composition comprises at least one metabolite of Fp, wherein the at least one metabolite is hypoxanthine. A use of the probiotic composition or hypoxanthine for manufacturing of a medicament for inhibiting the onset and progression of colorectal cancer.
Owner:THE CHINESE UNIVERSITY OF HONG KONG

Citrulline-reducing agent

To provide a citrulline-reducing agent for intraoral use.SOLUTION: The present invention provides a citrulline-reducing agent for intraoral use that contains vitamin B6. The citrulline-reducing agent for intraoral use inhibits citrulline production and / or secretion by intraoral bacteria such as those belonging to Porphyromonas, Fusobacterium, Prevotella, Veillonella, Treponema, or Streptococcus.SELECTED DRAWING: None
Owner:LION CORP

Fusobacterium controlling composition and use thereof

The present invention addresses the problem of controlling Fusobacterium with a method that is considered to have little influence on beneficial bacteria. Provided is a Fusobacterium controlling composition comprising water soluble dietary fiber. The water soluble dietary fiber is preferably isomaltodextrin.
Owner:MEIJI CO LTD

Biomarker combination for diagnosing abdominal aortic aneurysm

The invention discloses a biomarker combination for diagnosing abdominal aortic aneurysm. The biomarker combination comprises seven differential bacteria, namely fusobacterium, Rombout, clostridium XIVb type Clostridium XIVb, Lactobacillus, Roseburia, Asaccharobacter, and Helicobacter, and is characterized in that the biomarker combination comprises seven differential bacteria, namely fusobacterium, Rombout, Clostridium XIVb type Clostridium XIVb, Lactobacillus, Roseburia, Asaccharobacter, and Helicobacter. According to the invention, a biomarker combination for diagnosing the abdominal aortic aneurysm is established by utilizing a microbiological omics technology, and a new strategy is provided for early diagnosis of the abdominal aortic aneurysm.
Owner:THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE

Kit and method for identifying multiple fluorescent quantitative PCR (Polymerase Chain Reaction) of fusobacterium

The invention discloses a multiplex fluorescent quantitative PCR kit for identifying fusobacterium, which comprises reaction solutions A, each group of reaction solutions A comprises a specific primer, a specific probe, an internal standard and a buffer solution of at least one target bacterium; the reaction liquid B comprises a hot start Taq antibody enzyme, a UDG enzyme and dNTPs (deoxyribonucleoside triphosphates); the standard solution comprises host cell nucleic acid; the reference substance comprises plasmids of fragments of all target bacteria and host cell nucleic acid. The invention further provides a multiple fluorescent quantitative PCR method for identifying the fusobacterium, and the multiple fluorescent quantitative PCR kit for identifying the fusobacterium is adopted. According to the application, the screened specific genetic marker is utilized, and the highly specific primer is designed based on the specific genetic marker, so that the combination efficiency of the primer and the probe is improved, the cross reaction of the primer and the formation of a primer dimer are avoided, and the specific genetic marker is obtained through reasonable combination of different target bacteria. According to the invention, simultaneous detection of multiple targets can be realized.
Owner:ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY +1

Biomarker for predicting severe condition of COVID-19 patient and application of biomarker

The invention discloses a biomarker for predicting severe treatment of a COVID-19 patient and application of the biomarker, and relates to the technical field of biomedicine. According to the invention, a COVID-19 patient severity prediction or auxiliary prediction model which is obtained by constructing biomarkers including Gemelia haemolsos, Streptococcus sp.A12, Fusobacterium pseudoperiodontium, Gemelia mollissima, Villonella atypical, Villonella rogosa and Prevotella melaninogena is found, the model is used for predicting and evaluating the severity of the COVID-19 patient, the sensitivity is high, and the specificity is good. The invention further discloses a method for predicting and evaluating the severity of the COVID-19 patient severity, and the method has the advantages that the method can be used for predicting and evaluating the severity of the COVID-19 patient severity;
Owner:SUN YAT SEN UNIVERSITY SHENZHEN +1

Composition used for removal of fusobacterium and / or streptococcus bacteria

To provide a novel technique for removal of Fusobacterium and / or Streptococcus bacteria.SOLUTION: The foregoing problem is solved by a composition for removal of Fusobacterium and / or Streptococcus bacteria, containing platinum nanoparticles and / or electrolyzed water as an active ingredient.SELECTED DRAWING: None
Owner:MR WATERMAN CO LTD +1

Application of biomarkers in the preparation of products for diagnosing patients with oral diseases and kits for detecting oral diseases

The present application discloses an application of a biomarker in the preparation of a product for diagnosing patients with oral diseases and a kit for detecting oral diseases, wherein the oral diseases include at least one of periodontitis, gingivitis and caries, and the biomarkers include cytokines and / or oral microorganisms, wherein the cytokines include at least one of IFN-γ, IL-6, IL-10, IL-18 and IL-1β, and the oral microorganisms include at least one of Neisseria, Porphyromonas, Fusobacterium and Treponema. In the present application, auxiliary diagnosis of oral diseases can be achieved by detecting biomarkers, which is conducive to timely detection of the condition in the early stage of oral diseases or before the disease progresses for timely intervention.
Owner:GUANGZHOU STARS PULSE CO LTD

Composition for use in removing Fusobacterium and / or Streptococcus

To provide a novel technique for removal of Fusobacterium and / or Streptococcus bacteria.SOLUTION: The foregoing problem is solved by a composition for removal of Fusobacterium and / or Streptococcus bacteria, containing platinum nanoparticles and / or electrolyzed water as an active ingredient.SELECTED DRAWING: None
Owner:MR WATERMAN CO LTD +1

Clostridium pralaense capable of improving metabolism-related steatohepatitis and application of clostridium pralaense

ActiveCN119265085Aimprove lesionInhibit expressionBacteriaMetabolism disorderFaecalibacterium prausnitziiLiver fibrosis
The invention relates to the technical field of biology, and particularly discloses clostridium praeparatum capable of improving metabolism-related steatohepatitis and application of the clostridium praeparatum. The clostridium pralaense is Faecalibacteria pralausnitziiGZSY3214, the clostridium pralaense is preserved in the Guangdong Microbial Culture Collection Center on August 7, 2024, and the preservation number of the clostridium pralaense is GDMCC (China General Microbiological Culture Collection Center) No: 64992. The clostridium pralaense has been preserved in the Guangdong Microbial Culture Collection Center on August 7, 2024. After being treated by the clostridium pralaense, the clostridium pralaense has a good curative effect on improving the progress of metabolism-related steatohepatitis diseases, and has a remarkable inhibition effect on NF-kB and MAPK signal pathways, participating in inflammatory reaction, of the liver; wherein the strain can also improve liver function and lipid metabolism, down-regulate contents of ALT, AST, TG, LDL and the like, inhibit expression of inflammation-related inflammatory cytokines and chemotactic factors, and significantly inhibit expression of liver fibrosis-related collagen and transforming growth factor-beta.
Owner:GUANGZHOU FIRST PEOPLES HOSPITAL (GUANGZHOU DIGESTIVE DISEASE CENT GUANGZHOU FIRST PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV THE SECOND AFFILIATED HOSPITAL OF SOUTH CHINA UNIV OF TECH)

Exhaled condensate microbial bacterial genus combination, kit and its application in predicting cough after COVID-19 infection

The present invention discloses an exhaled condensate microbial genus combination, a kit and an application in predicting cough after COVID-19 infection; the microbial genus combination includes Streptococcus, Haemophilus, Achromobacter, Neisseria, Roseburia, Geminicoccus and Fusobacterium, which can be used as a microbial genus combination marker for predicting patients with cough after COVID-19 infection, and has the advantages of high sensitivity and high specificity in predicting cough after COVID-19 infection, providing a powerful reference for clinical prediction.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

Multifunctional bacterial bio-conjugate integrating targeted delivery, oxygen generation, photodynamic therapy and immune activation and preparation method of multifunctional bacterial bio-conjugate

The invention relates to a multifunctional bacterial bio-conjugate integrating targeted delivery, oxygen generation, photodynamic therapy and immune activation and a preparation method thereof, CaO2 nanoparticles (CaO2 NPs) are synthesized through a calcium salt deposition method, a photosensitizer chlorin e6 (Ce6) is loaded on the surface of the CaO2 NPs through an ingenious design, then tannic acid (TA) is used for packaging, and the multifunctional bacterial bio-conjugate is prepared. The stable core-shell structure (TAat-CaO2 / Ce6) is obtained. A large number of phenolic hydroxyl groups, aromatic rings and galloyl groups on the surface of TA are utilized to form chemical coupling with rich functional groups on the surface of bacteria, so that the TA is loaded on the surface of the bacteria, and effective combination of a TA-coated CaO2 / Ce6 compound and fusobacterium nucleatum (Fn) is realized; and finally, the multifunctional bacterial bio-conjugate Fn-TA (at) CaO2 / Ce6 integrating targeted delivery, oxygen generation, photodynamic therapy and immune activation is successfully constructed.
Owner:STOMATOLOGICAL HOSPITAL TIANJIN MEDICAL UNIV

Method for detecting bacteria of genus fusobacterium in order to diagnose endometriosis

A method for detecting a Fusobacterium bacterium for diagnosing endometriosis according to one aspect of the present invention includes a step of detecting a Fusobacterium bacterium in a sample collected from a subject, wherein the detection of the presence of the Fusobacterium bacterium in the sample indicates that the subject is likely suffering from or likely to suffer from endometriosis. According to the present invention, a simple diagnosis of endometriosis becomes possible by detecting the causative bacterium of endometriosis.
Owner:NAT UNIV CORP TOKAI NAT HIGHER EDUCATION & RES SYST +1

Genetically modified fusiform strains and uses thereof

The present invention relates to genetically modified strains of Clostridium which provide an improved combination of replication and physiological properties useful for a variety of clinical and industrial applications. In particular, clinical grade spores produced from the Clostridium strains described herein can be efficiently stored, formulated, and advantageously used for the prevention and / or treatment of medical conditions such as cancer.
Owner:LIVENMADE BIOTECHNOLOGY CO LTD

Polypeptides of Fusobacterium and methods of use

The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
Owner:VAXXINOVA US INC

A prebiotic composition for proliferating intestinal beneficial flora and a method for preparing the same

The application discloses a prebiotic composition for proliferating intestinal beneficial bacteria and a preparation method thereof, and comprises the following raw materials in parts by weight: partially hydrolyzed composite glue 35-45 parts, resistant starch of green banana 30-40 parts, enzymatic okra polysaccharide 15-25 parts, and tea polyphenol 3-5 parts. The composition realizes efficient proliferation of intestinal beneficial bacteria and comprehensive and positive regulation of intestinal microenvironment by scientifically compounding partially hydrolyzed composite glue with a specific molecular weight, resistant starch of green banana, enzymatic okra polysaccharide and tea polyphenol. The four components with complementary functions and different effects can not only more efficiently proliferate traditional beneficial bacteria such as bifidobacterium and lactobacillus, but also effectively nourish butyric acid bacteria such as prasrmanella, and inhibit the growth of harmful bacteria, thereby having the functions of significantly improving intestinal flora disorder caused by ampicillin and promoting the generation of short-chain fatty acids and maintaining the intestinal barrier.
Owner:HUBEI TIME SEED LIFE TECH CO LTD

A marker combination related to postoperative prognosis of colorectal cancer and application and prediction system thereof

PendingCN122235339AComponent separationEnsemble learningPeptostreptococcusArginine
This invention belongs to the fields of bioinformatics and medical testing technology, specifically relating to a combination of biomarkers related to the postoperative prognosis of colorectal cancer and their application and prediction system. This invention, through 16S rRNA gene sequencing of tumor mucosal samples from colorectal cancer patients, combined with long-term postoperative follow-up data and screening, found that *Peptostreptococcus*, *Fusobacterium*, *Bacteroides*, *Porphyromonas*, and *Prevotella* are closely related to postoperative recurrence of colorectal cancer, with an AUC of 0.81 for assessing postoperative recurrence. Based on this, this invention conducts non-targeted metabolomics analysis, finding that combining alanine glutamate, putrescine, arginine, histidine, and sebacic acid with the above microbial biomarkers can improve the AUC to 0.91, significantly enhancing accuracy, specificity, and precision. This enables prognostic stratification of recurrence-free survival in colorectal cancer patients, demonstrating higher predictive efficacy and stability.
Owner:NANKAI UNIV +1

Selective solubilization of gangue from nickel sulfides using biosolvents

PCT designated stage expiredWO2025097162A1Process efficiency improvementAcetobacterRhizopus
A mixture includes a nickel-containing ore and / or concentrate thereof and an extraction composition including a fermentation broth obtained from an Aspergillus species (spp.), Acetobacter spp., Bacillus spp., Propionibacterium spp., Corynebacterium spp., Rhizopus spp., Clostridium spp., Fusobacterium spp., Pseudomonas spp., Bifidobacterium spp., Saccharomyces spp., Enterobacter spp., Escherichia spp., among others. The extraction composition is configured to selectively solubilize one or more components, such as a magnesium component from the nickel-containing ore and / or concentrate thereof. A method for extracting a metal from a nickel-containing ore and / or concentrate includes selectively solubilizing a magnesium component from the nickel-containing ore and / or concentrate thereof into an extraction composition including the fermentation broth. The method can include extracting a magnesium component from a nickel-containing ore and / or concentrate thereof into an extraction composition, separating the nickel-containing ore and / or concentrate thereof from an extracted magnesium component and broth, separating the broth from the extracted magnesium component, and repeating the extracting. The extracted magnesium component has a purity in a range from 10% to 90%.
Owner:ALLONNIA LLC

Application of chaxiong polysaccharide in the preparation of drugs for regulating intestinal flora in inflammatory bowel disease

The present invention discloses an application of tea lovage polysaccharide in the preparation of a drug for regulating intestinal flora in inflammatory bowel disease, and belongs to the technical field of polysaccharide extraction process optimization and intestinal flora regulation. Specifically, the present invention provides an economical and efficient extraction process and new use of tea lovage polysaccharide for the preparation of a preparation or composition. By increasing the relative abundance of probiotic flora, reducing the relative abundance of harmful bacteria, regulating the structure of intestinal flora, etc., the symptoms of intestinal flora disorder in inflammatory bowel disease are alleviated and treated. Tea lovage polysaccharide improves ulcerative colitis in mice by upregulating the relative abundance of probiotics such as Bacteroides and Faecalibacterium prausnitzii, and downregulating the relative abundance of pathogenic bacteria such as Proteobacteria, Gammaproteobacteria, Enterobacteriaceae and Escherichia, thereby reversing the abnormal proliferation of bacteria in mice with inflammatory bowel disease and improving the disordered intestinal flora in mice with inflammatory bowel disease.
Owner:INSTITUTE OF TCM HEALTH INDUSTRY CACMS

Composition for controlling fusobacterium and use thereof

The present invention addresses the problem of controlling a fusobacterium bacterium by means of a method which is believed to have little influence on beneficial bacteria. The present invention provides a composition for controlling bacteria belonging to the genus fusobacterium in the digestive tract, particularly in the oral and intestinal flora, comprising any one selected from the group consisting of flavonoids and sugar transporters thereof that dissociate a compound represented by formula I in the digestive tract, and the compounds represented by formula I. The composition can be used for controlling the bacteria belonging to the genus fusobacterium in the digestive tract, particularly in the oral and intestinal flora.
Owner:MEIJI CO LTD